The Safety of Lacosamide for Treatment of Seizures and Seizure Prophylaxis in Adult Hospitalized Patients

The Neurohospitalist

Volumn 2, Issue 3, 2012, Pages 77-81

  Luk, Marilyn E ^a   Tatum, William O ^b   Freeman, William D ^b   Patel, Alden V ^b   Nau, Karen M ^c  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c SUBURBAN HOSPITAL   (United States)

Author keywords

antiepileptic drugs; epilepsy; seizures; status epilepticus

Indexed keywords

EID: 84913603937     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941874412446200     Document Type: Article

References (19)

1. Kwan P Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342(5):314–319.
2. Abou Khaled KJ Hirsch LJ. Advances in the management of seizures and status epilepticus in critically ill patients. Crit Care Clin. 2006; 22(4):637–659.
3. Varelas PN Mirski MA. Management of seizures in critically ill patients. Curr Neurol Neurosci Rep. 2004; 4(6):489–496.
4. Knake S Hamer HM Rosenow F. Status epilepticus: a critical review. Epilepsy Behav. 2009; 15(1):10–14.
5. Isenstein D Nasraway SA. Hypotension during slow phenytoin infusion in severe sepsis. Crit Care Med. 1990; 18(9):1036–1038.
6. Kassab MY Lobeck IN Majid A Xie Y Farooq MU. Blood pressure changes after intravenous fosphenytoin and levetiracetam in patients with acute cerebral symptoms. Epilepsy Res. 2009; 87(2-3):268–271.
7. Ben-Menachem E Biton V Jatuzis D Abou-Khalil B Doty P Rudd GD, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48(7):1308–1317.
8. Perucca E Yasothan U Clincke G Kirkpatrick P. Lacosamide. Nat Rev Drug Discov. 2008; 7(12):973–974.
9. Doty P Rudd GD Stoehr T Thomas D. Lacosamide. Neurotherapeutics. 2007; 4(1):145–148.
10. Kellinghaus C Berning S Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009; 14(2):429–431.
11. Riela AR. Management of seizures. Crit Care Clin. 1989; 5(4):863–879.
12. Vimpat® (lacosamide). Prescriber information. UCB Inc, Smyrna, GA, April 20, 2011.
13. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009; 61(2):197–216.
14. Cross SA Curran MP. Lacosamide: in partial-onset seizures. Drugs. 2009; 69(4):449–459.
15. Landmark KE Johansen PW Johnson JA Johansen B Uran S Skotland T. Pharmacokinetics of perfluorobutane following intravenous bolus injection and continuous infusion of sonazoid in healthy volunteers and in patients with reduced pulmonary diffusing capacity. Ultrasound Med Biol. 2008; 34(3):494–501.
16. Biton V Rosenfeld WE Whitesides J Fountain NB Vaiciene N Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008; 49(3):418–424.
17. Tatum WO. Antiepileptic drug adverse effects and drug interactions. CONTINUUM: Lifelong Learn Neurol. 2010; 16(3):134–156.
18. Cherry S Judd L Muniz JC Elzawahry H Laroche S. Safety and efficacy of lacosamide in the intensive care unit. Neurocrit care. 2011; 16(2):294–298.
19. Sevcencu C Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia. 2010; 51(5):725–737.